Effect of Dapagliflozin in the Treatment of Obese Diabetes Mellitus Type 2 Patients with Poor Glycemic Control
Objective To investigate the clinical effect of dapagliflozin in the treatment of obese diabetes mellitus type 2 patients with poor blood glucose control.Methods A total of 104 obese patients with diabetes mellitus type 2 admitted to the the hospital from October 2022 to October 2023 were selected as the research objects.According to the random number table method,they were divided into a control group and an observation group,with 52 cases in each group.The control group was treated with metformin sustained-release tablets,and the observation group was treated with metformin sustained-release tablets combined with dapagliflozin.The blood glucose index,blood lipid index,islet function index,body mass index,abdominal circumference index and occurrence of adverse reactions were compared between the two groups.Results There were no significant differences in blood glucose,blood lipid,islet function,body mass index and abdominal circumference between the two groups before treatment(P＞0.05).After treatment,the levels of fasting plasma glucose,glycosylated hemoglobin,total cholesterol,triglyceride,low-density lipoprotein cholesterol,insulin resistance index,body mass index and waist circumference in the observation group were lower than those in the control group,the levels of islet β cell function index,fasting insulin and fasting C-peptide were higher than those in the control group,the differences between the two groups were statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Dapagliflozin is more effective than linagliptin in reducing blood glucose,blood lipid,improving islet function,reducing body weight and abdominal circumference,and it is more safe.
Type 2 diabetes mellitusObesityMetformin sustained-release tabletsDapagliflozin
NETL
NSTL
万方数据
